Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus.
about
Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference centerTeicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.3D printed bioceramics for dual antibiotic delivery to treat implant-associated bone infectionAn update on surgical and antimicrobial therapy for acute periprosthetic joint infection: new challenges for the present and the future.Influence of daily dosage and frequency of administration of rifampicin-levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections.Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study.False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia.The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.A molecular epidemiological study of methicillin-resistant Staphylococci environmental contamination in railway stations and coach stations in Guangzhou of China.Pristinamycin in the treatment of MSSA bone and joint infection.Hypokalemia during antibiotic treatment for bone and joint infections.The IMPROVE-GAP Trial aiming to improve evidence-based management of community-acquired pneumonia: study protocol for a stepped-wedge randomised controlled trial.False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia-authors' response.Efficacy of cloxacillin versus cefazolin for methicillin-susceptible bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial
P2860
Q34057545-8E3C87DA-4CDF-400F-A450-1178D01B2072Q35926840-9BDBFA33-C97C-4121-B139-2ADDC76323A8Q36181397-38CA1EF7-573F-420C-9D49-4AB6A36C55DFQ36328108-64D88FD3-2941-416E-A6E3-634FB972E413Q38314400-33A489DC-4E35-470E-8D5C-3A23E83C0D96Q38490164-02D44CEC-54CF-400F-9908-7FA5EC3C99B0Q39367796-FF3A621B-1D0C-466B-8B32-1EF659262256Q40172547-46B940EE-2DC2-4435-BEC6-1E01266DCA02Q40305775-6C19D733-7A26-46CC-AFE0-BCE89DBAA6E4Q40418309-2DA1F8DE-3F17-49E6-923F-883D5B846E15Q40821374-3C63AFF8-509C-4366-80B7-8ADF53CDA85AQ48212540-6A021351-AD6C-42CF-A5E8-FA73A80A4DFAQ50199469-0D3ED608-1B42-4400-824A-4F31115A79BFQ54755967-589C24A6-2FDA-4BC8-B5B7-A76CB11A6CA6Q58776515-3A20AE7D-1857-4859-8B73-4D948C297BDF
P2860
Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Antimicrobial-related severe a ...... eptible Staphylococcus aureus.
@en
Antimicrobial-related severe a ...... eptible Staphylococcus aureus.
@nl
type
label
Antimicrobial-related severe a ...... eptible Staphylococcus aureus.
@en
Antimicrobial-related severe a ...... eptible Staphylococcus aureus.
@nl
prefLabel
Antimicrobial-related severe a ...... eptible Staphylococcus aureus.
@en
Antimicrobial-related severe a ...... eptible Staphylococcus aureus.
@nl
P2093
P2860
P356
P1476
Antimicrobial-related severe a ...... eptible Staphylococcus aureus.
@en
P2093
Anissa Bouaziz
Christian Chidiac
Florence Ader
Florent Valour
Frédéric Laurent
Judith Karsenty
Lyon BJI Study Group
Michel Tod
René Ecochard
Sébastien Lustig
P2860
P304
P356
10.1128/AAC.02032-13
P407
P577
2013-11-18T00:00:00Z